Treatable traits in children with bronchiectasis - 20/02/26

Doi : 10.1016/j.prrv.2026.02.002

Joséphine Annereau ^a,^b, Apolline Gonsard ^a,^c, Rola Abou Taam ^a, Christophe Delacourt ^a,^c, Charlotte Roy ^a, Anaïs Le ^a,^c, Isabelle Sermet-Gaudelus ^a,^b,^d,^e, Alice Hadchouel ^a,^c, David Drummond ^a,^b,^c,^⁎

^a Department of Paediatric Pulmonology and Allergology, AP-HP, University Hospital Necker-Enfants Malades, F-75015 Paris, France

^b Université Paris Cité, Inria, Inserm, HeKA, F-75015 Paris, France

^c Université Paris Cité, Faculté de médecine, F-75015 Paris, France

^d Institut Necker Enfants Malades, INSERM U1151, Paris, France

^e European Rare Disease Network-Lung, Frankfurt Germany

^⁎ Corresponding author at: Service de pneumologie et d’allergologie pédiatrique, hôpital universitaire Necker–Enfants-Malades, 149, rue de Sèvres, 75015 Paris, France. Service de pneumologie et d’allergologie pédiatrique hôpital universitaire Necker–Enfants-Malades 149, rue de Sèvres Paris 75015 France

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Friday 20 February 2026

Graphical abstract

Le texte complet de cet article est disponible en PDF.

Educational Aims

The reader will come to appreciate:

•	A treatable traits (TT) framework provides a structured, precision-medicine approach that complements guidelines and ensures no modifiable factor is overlooked in children with bronchiectasis.
•	Forty TT can be identified across aetiological, pulmonary, extrapulmonary, and behavioural/environmental domains, reflecting the heterogeneity of paediatric bronchiectasisEvidence supporting many TT remains limited in children, highlighting the need for paediatric-specific trials to determine their true clinical impact.
•	Systematic identification and targeted management of TT may optimise outcomes by addressing the full spectrum of factors contributing to disease severity and exacerbation risk.

Le texte complet de cet article est disponible en PDF.

Abstract

Bronchiectasis in children is a heterogeneous, chronic respiratory condition for which standardised, evidence-based management is essential. While international guidelines have improved diagnostic and therapeutic consistency, the treatable traits (TT) approach offers a complementary precision-medicine framework aimed at identifying all clinically relevant, measurable, and modifiable factors in individual patients. Through a comprehensive literature review, we identified 40 potential TT in paediatric bronchiectasis, spanning aetiological, pulmonary, extrapulmonary, and behavioural/environmental domains. However, the level of evidence supporting many TT remains limited in children, with most data extrapolated from adults or other respiratory diseases. This framework should therefore be considered dynamic, guiding systematic assessment while emphasising the urgent need for paediatric-specific clinical trials.

Le texte complet de cet article est disponible en PDF.

Keywords : Bronchiectasis, Precision medicine, Paediatrics, Comorbidity, Traits, Medication adherence